RAD-140

evidence score

sarm

Research Only

39 studies

TestoloneRAD140LY-2452473 analog

RAD-140 (Testolone) is a highly potent oral SARM originally developed by Radius Health for hormone receptor-positive breast cancer. Phase I completed in breast cancer patients. In animal models it demonstrated near-anabolic-steroid-equivalent muscle growth with brain-protective (neuroprotective) effects via AR activation in neural tissue. Among the most potent SARMs by milligram. Significant testosterone suppression, liver toxicity cases reported. WADA-prohibited.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Phase I

Research Sync

Feb 19, 2026

Dosing

Typical

10 mg

5 mgRange20 mg

FrequencyOnce daily oral

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~60 hours

Onset2–3 weeks for strength; 6–8 weeks for body composition changes

DurationLong suppression recovery: 6–10 weeks

Routes

oral

Evidence Score

Level B — Moderate

39 studies indexed

Scoring Factors

Volume(40%)~32/100

Quality(30%)~40/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

RAD-140 is currently categorized as a sarm compound.

Evidence is moderate (61/100): promising signal from 39 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Potent selective AR agonist; high muscle:prostate anabolic ratio; also activates neuroprotective AR pathways in brain

Practical Context

Strongest current signals

Level D: Treatment with a selective androgen receptor modulator (RAD140) is linked to better cardiac function, with male-specific effects that are graded by interleukin-6.
Level D: Initial testing procedure based on microextraction followed by LC-HRMS analysis to determine 107 xenobiotics and their metabolites in serum/plasma.
Level D: Cholestatic Drug-Induced Liver Injury From Rad-140 Successfully Treated With Corticosteroids.

Elevated caution signals

2 severe/high side effect flags